PHILADELPHIA CREAM – (COMMERCIAL THREAD) – Aro Biotherapeutics, a pioneering biotechnology company in the development of genetic tissue-targeted drugs, today announced the appointment of three new executives, including Scott Greenberg as COO, Jeffrey Staiger as as Senior Vice President of Finance and Business Development, and Michael Tortorici, PharmD, Ph.D. as Vice President of Clinical Pharmacology and Non-Clinical Development. Mr. Greenberg recently served as Aro’s Commercial Director, while Mr. Staiger and Dr. Tortorici are new additions to the management team. The company also announced its intention to relocate its headquarters to Curtis in Philadelphia to accommodate the continued growth of its operations and staff.
“The expansion of our leadership team provides Aro with proven leadership expertise as we advance our first molecules into clinical development and continue to evolve our organization, âsaid Susan Dillon, Ph.D., co-founder and CEO of Aro Biotherapeutics. “I am happy to welcome Jeff and Mike to Aro. They both have extensive experience in their respective functional areas which will bring great value to our organization. In his expanded role, Scott and his team will help us develop additional business capabilities that will support our future growth. ”
Mr. Greenberg joined Aro in 2019 from Roivant Sciences, where he most recently served as Vice President, Chief Operating Officer. Previously, he worked at Celgene Corporation in several roles spanning business development, project management, strategy, sales and marketing. He began his career in investment banking at Goldman Sachs Group, Inc. and received an MBA from Harvard Business School.
Mr. Staiger is an international leader in finance and business development having spent over 13 years with Celgene / Bristol Myers Squibb, in roles spanning finance, clinical development, corporate strategy, business operations, leadership alliance and business development. Mr. Staiger began his career at PricewaterhouseCoopers, becoming a Chartered Accountant, and held positions in finance at Quest Diagnostics. He received degrees in economics and accounting from Gordon College (MA).
Dr Tortorici, PharmD, Ph.D. has 15 years of experience in the pharmaceutical industry in the field of clinical pharmacology for small molecules and biologics in a wide range of diseases. He was most recently Executive Director and Head of Clinical Pharmacology at CSL Behring, leading the team responsible for clinical pharmacology for all programs in the portfolio. Prior to that, he worked at Pfizer in clinical pharmacology. Dr Tortorici received his PharmD and Ph.D. in Pharmaceutical Sciences from the Faculty of Pharmacy at the University of Pittsburgh.
Beginning in October 2021, Aro will begin moving operations to the Curtis in downtown Philadelphia. The Curtis is one of the best places for the scientific community to develop and perfect life-saving therapies and attract world-class talent to achieve their goals. The expanded space will be customized to Aro’s needs, providing an ideal location for the development of Centyrin’s proprietary Aro platform – siRNA drugs. Aro plans to complete the move to The Curtis in the first quarter of 2022.
“We couldn’t be happier to move to the historic Curtis Building as we enter our next phase of growth, âsaid Dillon. “Lab and office spaces will help us create a world class facility, and with other building amenities and attractions nearby, The Curtis is ideal for Aro to hire and retain top talent.
About Aro Biotherapeutics
Philadelphia-based Aro Biotherapeutics is a pioneering biotechnology company in the development of tissue-targeted genetic drugs with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapies for a diverse set of diseases. For more information visit www.arobiotx.com.